Lantheus launches MR angio agent in Canada

Diagnostic imaging company Lantheus Medical Imaging has launched its injectable MR angiography (MRA) blood pool imaging agent, Ablavar, in Canada.

According to the North Billerica, Mass.-based company, the product is indicated for contrast-enhanced MRA for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. The agent was previously marketed in Canada as Vasovist.

Ablavar was released in the U.S. in January, and is indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease in the U.S., Lantheus added.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup